GMDA Research and Charts

GMDA - Gamida Cell Ltd (Healthcare: Biotechnology)

Projected Earnings Date: 0000-02-29 (Delayed quote data 2024-05-02)

Last 0.02	Change ⇓ 0.00 (0.00%)	Volume 265,168
	Open 0.02	High 0.02	Low 0.01

8EMA (Daily) 0.02	40EMA (Daily) 0.11	50EMA (Daily) 0.15	STO (Daily) 100.000	MACD Hist (Daily) 0.020
8EMA (Weekly) 0.097	40EMA (Weekly) 0.55	50EMA (Weekly) 0.69	STO (Weekly) 1.250	MACD Hist (Weekly) -0.004


Company Profile
Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.